SPDR Dow Jones Industrial Average ETF

SPDR S&P 500 ETF Trust

Invesco QQQ Trust Series 1

Trump Media & Technology Group Corp. engages in operating social media and in the technology business. Its brands include TRUTH Social, TMTG+, and TMTG News. It operates through the Media and Truth.Fi segments. The Media segment includes products and services such as advertisement through the Truth Social platform. The Truth.Fi segment relates to customized exchange-traded funds or exchange-traded products invested in America First principles, and bitcoin and similar cryptocurrencies or crypto-related securities. The company was founded on March 28, 2024 and is headquartered in Sarasota, FL.

Trump Media & Technology Group Corp.

Democratic gains in the midterms and the resulting political setback for Trump are the dominant focus, with traders linking the selloff in Trump Media to concerns about a weakened presidency, congressional gridlock, and potential investigations. The discussion is overwhelmingly bearish, though a few traders argue for buying the dip or a short squeeze.

Super Micro Computer, Inc. engages in the distribution and manufacture of information technology solutions and other computer products. Its products include twin solutions, MP servers, GPU and coprocessor, MicroCloud, AMD solutions, power supplies, SuperServer, storage, motherboards, chassis, super workstations, accessories, SuperRack and server management products. The company was founded by Charles Liang, Yih-Shyan Liaw, Sara Liu, and Chiu-Chu Liu Liang in September 1993 and is headquartered in San Jose, CA.

Super Micro Computer Inc

Super Micros strong quarterly results and raised outlook have drawn attention, but traders are frustrated that the stock sold off despite the news. The debate centers on whether concerns about data-center regulation after the midterms, thin margins, customer concentration and cash conversion outweigh the AI-server growth story; some view the decline as an overreaction, while others question managements credibility and execution.

Micron Technology, Inc. engages in the provision of innovative memory and storage solutions. It operates through the following segments: Cloud Memory Business Unit (CMBU), Core Data Center Business Unit (CDBU), Mobile and Client Business Unit (MCBU), and Automotive and Embedded Business Unit (AEBU). The CMBU segment focuses on memory solutions for large hyperscale cloud customers and High-Bandwidth Memory for all data center customers. The CDBU segment is involved in memory solutions for mid-tier cloud, enterprise, and OEM data center customers and storage solutions for all data center customers. The MCBU segment focuses on memory and storage solutions for the mobile and client segments. The AEBU segment is involved in memory and storage solutions for the automotive, industrial, and consumer segments. The company was founded by Ward D. Parkinson, Joseph Leon Parkinson, Dennis Wilson, and Doug Pitman on October 5, 1978 and is headquartered in Boise, ID.

Micron Technology Inc.

Micron Technology Inc

Micron is caught in a sharp semiconductor selloff as traders fear that Democrats election gains could bring tighter data-center rules or slow AI infrastructure spending, weakening future memory demand. Bulls call the reaction an overblown market rotation and point to persistent AI-driven memory demand, while bears see risks to data-center investment and a cyclical memory downturn.

IREN Ltd. is a vertically integrated data center business powering the future of Bitcoin, AI and beyond with renewable energy. It is strategically located in renewable-rich, fiber-connected regions across the US and Canada. IREN’s large-scale, grid-connected facilities are purpose-built for the next generation of power-dense computing applications. The company was founded by Daniel Roberts and William Roberts on November 6, 2018, and is headquartered in Sydney, Australia.

IREN Ltd.

IREN Limited

IREN is under pressure amid election-related fears that tighter Texas and data-center rules could slow AI infrastructure expansion, alongside uncertainty ahead of earnings. Traders debate whether those risks outweigh the value of its existing power and data-center buildout, with some also pointing to a Microsoft contract as a potential cushion.

Cipher Digital, Inc. operates as a Bitcoin mining ecosystem in the United States. The firm is developing a cryptocurrency business. The company was founded in 2021 and is headquartered in New York, NY.

Cipher Digital Inc.

Fears that a Democratic win in Texas could slow or restrict data-center approvals have driven a sharp selloff in CIFR and other AI-infrastructure stocks. Bears warn that delays could threaten future growth, while bulls argue signed leases and projects already underway are less exposed and that AI demand remains intact.

Apple, Inc. engages in the design, manufacture, and sale of smartphones, personal computers, tablets, wearables and accessories, and other varieties of related services. It operates through the following geographical segments: Americas, Europe, Greater China, Japan, and Rest of Asia Pacific. The Americas segment includes North and South America. The Europe segment consists of European countries, as well as India, the Middle East, and Africa. The Greater China segment comprises China, Hong Kong, and Taiwan. The Rest of Asia Pacific segment includes Australia and Asian countries. Its products and services include iPhone, Mac, iPad, AirPods, Apple TV, Apple Watch, Beats products, AppleCare, iCloud, digital content stores, streaming, and licensing services. The company was founded by Steven Paul Jobs, Ronald Gerald Wayne, and Stephen G. Wozniak in April 1976 and is headquartered in Cupertino, CA.

Apple Inc

Apples sharp rebound after its earnings-related selloff is driving attention, with traders describing a return to highs and debating whether a post-election rotation into mega-cap safe haven stocks and a short squeeze are behind the move. Bulls point to resilient demand and buying the dip, while skeptics question the rally given margin pressure from rising memory costs and Apples valuation.

Sandisk Corp. engages in the development, manufacture, and provision of storage devices and solutions based on NAND flash technology. Its products include solid state drives, memory cards, and USB flash drives. The company was founded on February 5, 2024 and is headquartered in Milpitas, CA.

Sandisk Corp

Sandisk is caught in a sharp memory-stock selloff as traders worry that election-related uncertainty could slow U.S. data-center expansion and weaken future AI memory demand, despite strong results and supply-shortage arguments. The community is split between viewing the decline as a buying opportunity ahead of the stock split and seeing it as a warning that the AI-memory trade has run too far or may face a cyclical downturn.

Advanced Micro Devices, Inc. engages in the semiconductor business. Its products include processors, accelerators, graphics, adaptive SoCs, FPGAs, and SOMs, and software, tools, and apps. The firm offers artificial intelligence, industries, workloads, and gaming solutions. The company was founded by W. J. Sanders III on May 1, 1969 and is headquartered in Santa Clara, CA.

Advanced Micro Devices Inc.

Advanced Micro Devices Inc

AMDs strong quarterly results and upbeat data-center outlook have been overshadowed by a sharp reversal that erased much of its post-earnings gain. Traders debate whether election-related worries about data-center restrictions and AI spending, valuation concerns, or profit-taking drove the fade; bulls view the pullback as an overreaction to the companys growth outlook.

Uber Technologies, Inc. is a technology platform, which engages in the development and operation of technology applications, networks, and product to power movement from point A to point B. The firm offers ride services and merchants delivery service providers for meal preparation, grocery, and other delivery services. It operates through the following segments: Mobility, Delivery, and Freight. The Mobility segment refers to products that connect consumers with mobility drivers who provide rides in a variety of vehicles, such as cars, auto rickshaws, motorbikes, minibuses, and taxis. The Delivery segment offers consumers the chance to search for and discover local restaurants, order a meal, and either pick-up at the restaurant or have the meal delivered. The Freight segment focuses on connecting carriers with shippers on its platform, and gives carriers upfront, transparent pricing, and the ability to book a shipment. The company was founded by Oscar Salazar Gaitan, Travis Kalanick, and Garrett Camp in 2009 and is headquartered in San Francisco, CA.

Uber Technologies Inc

UBER is drawing attention after Q3 results showed strong bookings growth and improving profitability, prompting a sharp rally. Traders are broadly bullish on the operating performance, while some question the softer Q4 outlook and weakness in Mobility revenue amid driver-supply concerns.

Vistra Corp. is a holding company, which engages in the provision of electricity and power generation. It operates through the following segments: Retail, Texas, East, West, and Asset Closure. The Retail segment includes sale of electricity and natural gas to residential, commercial, and industrial customers. The Texas and East segments are involved in electricity generation, wholesale energy sales and purchases, commodity risk management activities, fuel production and fuel logistics management. The West segment represents the company's electricity generation operations in CAISO. The Asset Closure segment refers to the decommissioning and reclamation of retired plants and mines. The company was founded in 1882 and is headquartered in Irving, TX.

Vistra Corp

Vistra is under heavy selling pressure after traders cited a KeyBanc downgrade tied to concerns that Texass Democratic election results could bring tighter data-center and energy-policy rules; the shares are also being discussed as part of a broader pullback in AI-power stocks. The community is split between viewing the move as an overreaction and buying opportunity, and worrying that political uncertainty could weigh on growth.

statis crypto Watchlist

Bitcoin

Ethereum

Solana

Ripple

Dogecoin

Cardano

statis IN Watchlist

Nifty 50

Nifty Bank

Reliance Industries Ltd.

Zomato Ltd.

Tata Consultancy Services

Tata Motors Ltd.

HDFC Bank Ltd.

ITC Ltd.

Adani Enterprises Ltd

Axis Bank Ltd

Bajaj Finance Ltd

statis US Watchlist

SPDR S&P 500 ETF

Apple Inc.

Tesla Inc

Microsoft Corporation

NVIDIA Corp

 Hey, I want to invite you to join Stocktwits. It’s the largest global community of active traders. You’ll get access to the real-time market insights, news, discussion and much more! You can sign up using my unique link below 
 


 has invited you to join Stocktwits

Wall Street Analysts See a 214.55% Upside in Regenxbio (RGNX): Can the Stock Really Move This High?

The average of price targets set by Wall Street analysts indicates a potential upside of 214.6% in Regenxbio (RGNX). While the effectiveness of this highly sought-after metric is questionable, the positive trend in earnings estimate revisions might translate into an upside in the stock.

4 Biotech Stocks Likely to Outpace Q3 Earnings Estimates

Four biotech stocks, including TG Therapeutics and Immunome, show positive Earnings ESPs and favorable Zacks Ranks, positioning them for potential third-quarter earnings beats.

AC Immune (ACIU) Reports Q3 Loss, Beats Revenue Estimates

AC Immune (ACIU) delivered earnings and revenue surprises of +27.27% and +299.42%, respectively, for the quarter ended September 2026. Do the numbers hold clues to what lies ahead for the stock?

REGENXBIO to Participate in Stifel 2026 Healthcare Conference

REGENXBIO to Participate in Stifel 2026 Healthcare Conference REGENXBIO to Participate in Stifel 2026 Healthcare ConferencePR NewswireROCKVILLE, Md., Nov. 3, 2026 ROCKVILLE, Md., Nov. 3, 2026 /PRNewswire/ --REGENXBIO Inc. (Nasdaq: RGNX) today announced it will participate in the Stifel 2026...

Regenxbio (RGNX) Expected to Beat Earnings Estimates: Should You Buy?

Regenxbio (RGNX) possesses the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

REGENXBIO to Host Conference Call on November 5 to Discuss Third Quarter 2026 Financial Results and Operational Highlights

REGENXBIO to Host Conference Call on November 5 to Discuss Third Quarter 2026 Financial Results and Operational Highlights REGENXBIO to Host Conference Call on November 5 to Discuss Third Quarter 2026 Financial Results and Operational HighlightsPR NewswireROCKVILLE, Md., Oct. 29, 2026 ROCKVILLE...

Stocktwits Pharma Pulse: Moderna-Merck Cancer Vaccine Grabs Spotlight As Kidney-Cancer And MS Data Pour In 

Equity

Humacyte, Vera, Maze and Climb Bio will present dialysis-access and kidney-disease findings at ASN Kidney Week.

REGENXBIO to Host Investor Event Highlighting Surabgene Lomparvovec (Sura-vec) in Wet AMD on October 20

REGENXBIO to Host Investor Event Highlighting Surabgene Lomparvovec (Sura-vec) in Wet AMD on October 20 REGENXBIO to Host Investor Event Highlighting Surabgene Lomparvovec (Sura-vec) in Wet AMD on October 20PR NewswireROCKVILLE, Md., Oct. 12, 2026Event to include clinical program overview and...

Regenxbio’s Two Lead Gene Therapies Back Mizuho’s Nearly 200% Upside Call

Mizuho initiated coverage of Regenxbio with an ‘Outperform’ rating and a $22 price target.


REGENXBIO Presents Positive Three-Year Durability Data for Surabgene Lomparvovec in Diabetic Retinopathy at Retina Society Annual Scientific Meeting

REGENXBIO Presents Positive Three-Year Durability Data for Surabgene Lomparvovec in Diabetic Retinopathy at Retina Society Annual Scientific Meeting REGENXBIO Presents Positive Three-Year Durability Data for Surabgene Lomparvovec in Diabetic Retinopathy at Retina Society Annual Scientific MeetingPR...

REGENXBIO, Inc. is a clinical-stage biotechnology company, which engages in the development, commercialization, and licensing of recombinant adeno-associated virus gene therapy. Its product candidates include the NAV Technology Platform, which consists of exclusive rights to novel adeno-associated viral vectors, and therapeutic programs such as RGX-314, RGX-202, RGX-121, RGX-111, RGX-181, and RGX-381. The company was founded by Kenneth T. Mills and James M. Wilson on July 16, 2008 and is headquartered in Rockville, MD.

Regenxbio Inc

Bearish Sentiment

<ul class="summary-bullets"><li><a class="mention" data-mention="$MRNA" data-symbol-id="MRNA" href="https://stocktwits.com/symbol/MRNA" target="_blank">Moderna</a> and Merck will present Phase 3 melanoma findings on Saturday for their personalized cancer treatment combined with Keytruda.</li><li>Arcus will share Casdatifan kidney-cancer data on Tuesday, while Achieve presents yearlong smoking and vaping cessation findings.</li><li>TG Therapeutics and Kyverna will present CAR-T findings in neurological diseases, including progressive multiple sclerosis.</li></ul><p>The biotech spotlight will move from kidney cancer to Huntington’s disease and personalized cancer treatment this week, as Arcus Biosciences (RCUS), Alnylam (ALNY), Moderna (MRNA) and Merck (MRK) deliver clinical updates amid a busy schedule of earnings and medical conferences.</p><p>The<a href="https://stocktwits.com/symbol/XLV">&nbsp;Health Care Select Sector SPDR Fund (XLV)</a> gained 3% last week, outperforming the<a href="https://stocktwits.com/symbol/SPY">&nbsp;SPDR S&amp;P 500 ETF Trust (SPY)</a>, which fell 2%, and the<a href="https://stocktwits.com/symbol/QQQ">&nbsp;Invesco QQQ Trust (QQQ)</a>, down 6%. The<a href="https://stocktwits.com/symbol/IBB">&nbsp;iShares Biotechnology ETF (IBB)</a> declined 2.2%, trailing SPY but holding up better than QQQ, while the<a href="https://stocktwits.com/symbol/XBI">&nbsp;SPDR S&amp;P Biotech ETF (XBI)</a> dropped 6%.</p><p><img src="https://news.stocktwits-cdn.com/pharma_pulse_14c016fc9d.png" alt="pharma pulse.png"></p><p>&nbsp;</p><div><figure class="table"><table class="ck-table-resized"><colgroup><col><col><col></colgroup><tbody><tr><td>Date</td><td>Ticker/Event</td><td>Development</td></tr><tr><td>Oct.19</td><td>EPRX / UEG Week</td><td>Oral presentation on tissue changes following EP-104GI treatment in eosinophilic esophagitis</td></tr><tr><td>Oct.19</td><td>IMTX / TNGX / ORIC</td><td>Scheduled publication of regular ESMO abstracts</td></tr><tr><td>Oct.20</td><td>RCUS</td><td>New ARC-20 Casdatifan kidney-cancer finding and investor event&nbsp;</td></tr><tr><td>Oct.20</td><td>ACHV / CHEST</td><td>Presentation of 52-week ORCA-OL Cytisinicline efficacy data</td></tr><tr><td>Oct.20</td><td>RGNX</td><td>Sura-vec wet-AMD investor event&nbsp;</td></tr><tr><td>Oct.21</td><td>ABT / DHR / TMO</td><td>Q3 results</td></tr><tr><td>Oct.21</td><td>KYTX / IMUX</td><td>Stiff person syndrome and progressive MS presentations</td></tr><tr><td>Oct.22</td><td>RHHBY / ARGX</td><td>Roche’s quarterly sales update and Argenx’s results</td></tr><tr><td>Oct.22</td><td>VERA / HUMA</td><td>Origin 3 kidney-disease analysis and interim Phase 3 dialysis-access findings</td></tr><tr><td>Oct.22</td><td>TGTX / ZBIO</td><td>Briumvi, Obexelimab and Orelabrutinib presentations</td></tr><tr><td>Oct.23</td><td>ALNY / TGTX / KYTX</td><td>Huntington’s disease and progressive-MS clinical updates</td></tr><tr><td>Oct 23</td><td>TNGX</td><td>Pancreatic-cancer investor webcast</td></tr><tr><td>Oct.23</td><td>IMTX / BHVN / CATX</td><td>Early-stage cancer-treatment presentations at ESMO</td></tr><tr><td>Oct.24</td><td>MRNA / MRK / CMPX / IMTX</td><td>Melanoma, biliary tract cancer and Prame-program findings</td></tr><tr><td>Oct.24</td><td>VERA / MAZE / CLYM</td><td>Clinical presentations at ASN Kidney Week</td></tr></tbody></table></figure></div><h2 class="st-heading-2"><strong>Arcus And Achieve Lead Early Data Watch</strong></h2><p>Arcus Biosciences (RCUS) will present kidney-cancer findings on Tuesday from its ARC-20 study of Casdatifan. The update covers initial treatment combinations: Casdatifan plus Cabozantinib in 43 previously treated patients, and Casdatifan alone in 121 more heavily treated patients. Median follow-up is about 21 months for the Cabozantinib combination and 28 months for Casdatifan alone.</p><p>Achieve Life Sciences (ACHV) will present year-long Cytisinicline findings on Tuesday at CHEST in Phoenix. The ORCA-OL study enrolled 475 adults who smoked or vaped and received the drug alongside behavioral support. Results include lab-confirmed measures of quitting. Achieve plans to resubmit its smoking-cessation application in the fourth quarter after a June FDA rejection that the company said concerned manufacturing and labeling, with no clinical efficacy or safety deficiencies identified.</p><p>Eupraxia Pharmaceuticals (EPRX) will present on Monday at UEG Week in Barcelona on tissue changes following EP-104GI treatment for eosinophilic esophagitis, an inflammatory condition that can make swallowing difficult. The findings come from the early, open-label Resolve study, while interim results from its randomized Phase 2b portion are expected in December.</p><p>RegenXBio (RGNX) will review its sura-vec treatment for wet age-related macular degeneration at a Tuesday investor event ahead of trial results expected in the fourth quarter.</p><h2 class="st-heading-2"><strong>Roche And Argenx Take Results Spotlight</strong></h2><p>Roche (RHHBY) will report third-quarter sales on Thursday. First-half sales grew 6%, excluding currency effects but fell 2% in Swiss francs. Growth was led by Xolair, Hemlibra, Ocrevus, Phesgo and Vabysmo.</p><p>Argenx (ARGX) also reported on Thursday, following positive Phase 2 findings for its celiac-disease treatment FB102 and its decision to stop its Phase 3 Sjogren’s disease trial after an interim analysis indicated it was unlikely to succeed. Abbott (ABT), Danaher (DHR) and Thermo Fisher Scientific (TMO) report on Wednesday.</p><h2 class="st-heading-2"><strong>Neurological CAR-T Studies In Focus</strong></h2><p>TG Therapeutics (TGTX) will present its first Phase 1 Azer-cel results in primary progressive multiple sclerosis (MS) on Friday at MSToronto2026, with the full abstract due Wednesday. The treatment uses genetically modified donor immune cells. Other presentations cover seven-year Briumvi outcomes, findings from routine care and a simplified initial dosing schedule.</p><p>Kyverna Therapeutics (KYTX) will present one-year Phase 2 Kysa-8 findings for miv-cel in stiff person syndrome on Wednesday, followed by updated results from a physician-led Phase 1 study in progressive MS on Friday.</p><p>Immunic (IMUX) will share longer-term progressive-MS findings from Calliper on&nbsp; Wednesday. Zenas BioPharma (ZBIO) follows on Thursday with Phase 2 MS findings for Obexelimab and Orelabrutinib.</p><h2 class="st-heading-2">Huntington’s And Cancer Data Close Trading Week</h2><p>Alnylam Pharmaceuticals (ALNY) will present initial Phase 1 ALN-HTT02 results on Friday at the European Huntington’s Disease Network congress in Krakow. Developed with Regeneron, the investigational RNA-interference treatment targets huntingtin, the protein implicated in Huntington’s disease.</p><p>Tango Therapeutics (TNGX) will hold a pancreatic-cancer webcast on Friday discussing Vopimetostat combined with Daraxonrasib or Zoldonrasib. The study involves patients with MTAP-deleted, RAS-mutant cancers.&nbsp;</p><h2 class="st-heading-2"><strong>Kidney Week Puts HUMA And VERA In Focus</strong></h2><p>Humacyte (HUMA) will present interim Phase 3 V012 results on Thursday, comparing its tissue-engineered vessel with a conventional fistula for dialysis access in women with end-stage kidney disease. The company targets a supplemental FDA application this quarter.</p><p>Vera Therapeutics (VERA) will present its Origin 3 final efficacy analysis on Thursday, following the September announcement of the results. Saturday brings separate interim Phase 2 Pioneer findings in IgA nephropathy and primary membranous nephropathy.</p><p>Maze Therapeutics (MAZE) presents additional detail from its previously reported Phase 2 Horizon kidney-disease study on Saturday. Climb Bio (CLYM) presents healthy-volunteer CLYM116 findings on Thursday and preliminary Phase 2 Budoprutug results in primary membranous nephropathy on Saturday.</p><h2 class="st-heading-2"><strong>Moderna And Merck Lead ESMO’s Saturday Watchlist</strong></h2><p>ESMO opens on Friday in Madrid. Moderna (MRNA) and Merck (MRK) will present Phase 3 INTerpath-001 melanoma findings on Saturday, testing individualized treatment intismeran autogene plus Keytruda against Keytruda alone after surgery.</p><p>The companies previously announced improvements in recurrence-free and distant-metastasis-free survival. Overall-survival evaluation continues. Moderna will also host an investor webcast on Saturday.</p><p>Compass Therapeutics (CMPX) presents Companion-002 findings on Saturday. Tovecimig plus Paclitaxel improved response rates and progression-free survival in previously treated biliary tract cancer, but did not demonstrate a statistically significant overall-survival benefit. Compass says the FDA recommended another trial demonstrating a survival benefit before an application.</p><p>Immatics (IMTX) presents IMA203CD8 cell-therapy findings on Friday, followed Saturday by IMA402 bispecific data and Anzu-cel melanoma follow-up. Biohaven (BHVN), Perspective Therapeutics (CATX) and Eikon Therapeutics (EIKN) also have early-stage cancer presentations on Friday.</p><p>Additional presentations include Incyte’s (INCY) CDK2-inhibitor findings on Friday and colorectal-cancer bispecific data on Saturday, alongside Regeneron’s (REGN) final Phase 2 analysis of Cemiplimab before surgery in cutaneous squamous-cell carcinoma on Saturday.</p><p><i>For updates and corrections, email newsroom[at]stocktwits[dot]com.</i></p><p>Read Next:&nbsp;<a href="https://stocktwits.com/news-articles/markets/equity/tsla-stock-musk-tesla-value-optimus-cybercab-analyst-flying-halo-car-luring-buyers/cZx8eXmRBtv">TSLA Stock Rises Overnight: Musk Bets Tesla’s Value On Optimus, Cybercab — Analyst Sees Flying ‘Halo Car’ Luring Buyers&nbsp;</a></p>

In this photo illustration, silhouette of hands in medical gloves hold a medical syringe and a vial in front of Pfizer,Biontech,AstraZeneca,Moderna,Johnson & johnson,Novavax,Merck and Janssen logos. (Photo Illustration by Pavlo Gonchar/SOPA Images/LightRocket via Getty Images)

Stocktwits Pharma Pulse: Moderna-Merck Cancer Vaccine Grabs Spotlight As Kidney-Cancer And MS Data Pour In

iShares Biotechnology ETF

Merck & Co Inc

Moderna Inc

Regeneron Pharmaceuticals, Inc.

TG Therapeutics Inc

Tango Therapeutics Inc

SPDR S&P Biotech ETF

Health Care Select Sector SPDR Fund

Hold rates steady

Cut 25 bps

Hike 25 bps

Fed decision day is here - Kevin Warsh chairs his first FOMC meeting with markets pricing a hold at 3.50%-3.75% but watching for a hawkish shift. Vote on what you expect to be decided today, then drop your prediction for the first rate cut or hike in the comments.

What do you expect the Fed to decide at its FOMC meeting today? 
 
Drop a comment with when you expect the first cut/hike to be.

Current Price	$7.81
Prev Close	$7.63
Open	$7.74
Dividend Yield	0.00%
50-Day Moving Average	$7.90
Beta	1.75
Avg. Volume	1.38M
PE Ratio	-2.02

52-Week High	$16.19
52-Week Low	$5.46
Market Capitalization	$503.68M
EPS (Annual)	-$3.76
Price to Book	5.76
Revenue Per Employee	$459,409.70

Feed

News

Sentiment

Earnings

Fundamentals

Info

RGNX Fundamentals